Release of soluble tumor necrosis factor receptor 1 from corneal epithelium by TNF-α-converting enzyme-dependent ectodomain shedding

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 10, 2009, Pages 4618-4621

  Sakimoto, Tohru ^a   Yamada, Ai ^a   Sawa, Mitsuru ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALI; PHORBOL 13 ACETATE 12 MYRISTATE; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR RECEPTOR 1; ADAM PROTEIN; DIPEPTIDE; HYDROXAMIC ACID; N ((2 (HYDROXYAMINOCARBONYL)METHYL) 4 METHYLPENTANOYL) 3 (2' NAPHTHYL)ALANYLALANINE, 2 AMINOETHYLAMIDE; N-((2-(HYDROXYAMINOCARBONYL)METHYL)-4-METHYLPENTANOYL)-3-(2'-NAPHTHYL)ALANYLALANINE, 2-AMINOETHYLAMIDE; PEPTIDOGLYCAN; SODIUM HYDROXIDE; TNFRSF1A PROTEIN, MOUSE; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CONJUNCTIVA EPITHELIUM; CONTROLLED STUDY; CORNEA EPITHELIUM; CULTURE MEDIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN SECRETION; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CHEMICAL BURN; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; ENZYME IMMUNOASSAY; EYE BURN; METABOLISM; SOLUBILITY;

ADAM PROTEINS; ANIMALS; BURNS, CHEMICAL; CELL LINE, TRANSFORMED; DIPEPTIDES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIUM, CORNEAL; EYE BURNS; HUMANS; HYDROXAMIC ACIDS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED BALB C; PEPTIDOGLYCAN; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SODIUM HYDROXIDE; SOLUBILITY; TETRADECANOYLPHORBOL ACETATE; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

EID: 70349582731     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2669     Document Type: Article

References (35)

1. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10:45-65.
2. Levine SJ, Adamik B, Hawari FI, et al. Proteasome inhibition induces TNFR1 shedding from human airway epithelial (NCI-H292) cells. Am J Physiol Lung Cell Mol Physiol. 2005;289:L233-L243.
3. Blobel CP. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol. 2005;6:32-43.
4. Huovila AP, Turner AJ, Pelto-Huikku M, et al. Shedding light on ADAM metalloproteinases. Trends Biochem Sci. 2005;30:413-422.
5. Xanthoulea S, Pasparakis M, Kousteni S, et al. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med. 2004;200:367-376.
6. Pinckard JK, Sheehan KC, Arthur CD, Schreiber RD. Constitutive shedding of both p55 and p75 murine TNF receptors in vivo. J Immunol. 1997;158:3869-3873.
7. Van Zee KJ, Kohno T, Fischer E, et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A. 1992;89: 4845-4849.
8. Diez-Ruiz A, Tilz GP, Zangerle R, et al. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol. 1995;54:1-8.
9. Parsons PE, Matthay MA, Ware LB, et al. Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2005;288:L426-L431.
10. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97:133-144.
11. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385:729-733.
12. Moss ML, Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature. 1997;385:733-736.
13. Peschon JJ, Slack JL, Reddy P, et al. An essential role for ectodomain shedding in mammalian development. Science. 1998;282: 1281-1284.
14. Sahin U, Weskamp G, Kelly K, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol. 2004;164:769-779.
15. Marin V, Montero-Julian F, Gres S, et al. Chemotactic agents induce IL-6Rα shedding from polymorphonuclear cells: involvement of a metalloproteinase of the TNF-alpha-converting enzyme (TACE) type. Eur J Immunol. 2002;32:2965-2970.
16. Reddy P, Slack JL, Davis R, et al. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem. 2000;275:14608-14614.
17. Althoff K, Reddy P, Voltz N, et al. Shedding of interleukin-6 receptor and tumor necrosis factor alpha: contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. Eur J Biochem. 2000;267:2624-2631.
18. Sakimoto T, Yamada A, Kanno H, Sawa M. Upregulation of TNF receptor 1 and TNF-alpha converting enzyme during corneal wound healing. Jpn J Ophthalmol. 2008;52:393-398.
19. Hooper NM, Karran EH, Turner AJ. Membrane protein secretases. Biochem J. 1997;321(pt 2):265-279.
20. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 2003; 17:7-30.
21. Ikeda T, Funaba M. Altered function of murine mast cells in response to lipopolysaccharide and peptidoglycan. Immunol Lett. 2003;88:21-26.
22. Cook EB, Stahl JL, Graziano FM, Barney NP. Regulation of the receptors for TNFα, TNFR1, in human conjunctival epithelial cells. Invest Ophthalmol Vis Sci. 2008;49:3992-3998.
23. Mohan RR, Mohan RR, Kim WJ, Wilson SE. Modulation of TNF-alpha-induced apoptosis in corneal fibroblasts by transcription factor NF-κB. Invest Ophthalmol Vis Sci. 2000;41:1327-1336.
24. Kumar A, Zhang J, Yu FS. Innate immune response of corneal epithelial cells to Staphylococcus aureus infection: role of peptidoglycan in stimulating proinflammatory cytokine secretion. Invest Ophthalmol Vis Sci. 2004;45:3513-3522.
25. Weidenmaier C, Kristian SA, Peschel A. Bacterial resistance to antimicrobial host defenses-an emerging target for novel antiinfective strategies?. Curr Drug Targets. 2003;4:643-649.
26. Weskamp G, Schlöndorff J, Lum L, et al. Evidence for a critical role of the tumor necrosis factor alpha convertase (TACE) in ectodomain shedding of the p75 neurotrophin receptor (p75NTR). J Biol Chem. 2004;279:4241-4249.
27. Tsakadze NL, Sithu SD, Sen U, et al. Tumor necrosis factor-alphaconverting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). J Biol Chem. 2006;281:3157-3164.
28. Peiretti F, Canault M, Bernot D, et al. Proteasome inhibition activates the transport and the ectodomain shedding of TNF-alpha receptors in human endothelial cells. J Cell Sci. 2005;118:1061-1070.
29. Gómez MI, Sokol SH, Muir AB, et al. Bacterial induction of TNF-α converting enzyme expression and IL-6 receptor alpha shedding regulates airway inflammatory signaling. J Immunol. 2005;175: 1930-1936.
30. Wang J, Al-Lamki RS, Zhang H, et al. Histamine antagonizes tumor necrosis factor (TNF) signaling by stimulating TNF receptor shedding from the cell surface and Golgi storage pool. J Biol Chem. 2003;278:21751-21760.
31. Smookler DS, Mohammed FF, Kassiri Z, et al. Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J Immunol. 2006;176:721-725.
32. Armstrong L, Godinho SI, Uppington KM, Whittington HA, Millar AB. Contribution of TNF-α converting enzyme and proteinase-3 to TNF-α processing in human alveolar macrophages. Am J Respir Cell Mol Biol. 2006;34:219-225.
33. Cianci R, Cammarota G, Raducci F, Pandolfi F. The impact of biological agents interfering with receptor/ligand binding in the immune system. Eur Rev Med Pharmacol Sci. 2005;9:305-314.
34. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2:619-626.
35. Rosenwasser LJ, Meng J. Anti-CD23. Clin Rev Allergy Immunol. 2005;29:61-72.